LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Strona główna・Stock List・Alkermes PLC

Alkermes PLC

Closed

SectorHealthcare

28.63 1.06

Buy Sell

Overview

Share price change

24h

Current

Min

27.25

Max

28.73

Key metrics
By Trading Economics
Income	-275M -192M
Sales	-9.6M 385M
P/E Sector Avg	15.05 66.845
Profit margin	-50.013
Employees	2,050
EBITDA	-32M 77M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+56.26% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	-320M 5B
Previous open	27.57
Previous close	28.63

News Sentiment

By Acuity

17%

83%

26 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

27.95 / 30.91 Support & Resistance

Alkermes PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lis 2025, 12:22 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Pharma Sector Becoming Bidding Battlefield -- Market Talk

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

56.26% upside

12 Months Forecast

Average 44.3 USD 56.26%

High 58 USD

Low 34 USD

Based on 11 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Alkermes PLC - Dist in the past 3 months.

Technical Score

By Trading Central

27.95 / 30.91Support & Resistance

Bullish events outweigh bearish events.

All events are bearish.

All events are bullish.

Sentiment

By Acuity

26 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.